BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Deloitte
Mallinckrodt
McKesson
Dow
McKinsey
Citi
Novartis
Moodys
Merck

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,303,607

« Back to Dashboard

Which drugs does patent 6,303,607 protect, and when does it expire?

Patent 6,303,607 protects RANEXA and is included in one NDA.

This patent has ninety-two patent family members in twenty-nine countries.
Summary for Patent: 6,303,607
Title: Method for administering a sustained release ranolanolazine formulation
Abstract:A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.
Inventor(s): Wolff; Andrew A. (San Francisco, CA), Baker; Fiona (Dunfermline, GB), Langridge; John Richard (Wales, GB)
Assignee: CV Therapeutics, Inc. (Palo Alto, CA)
Application Number:09/321,522
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Drugs Protected by US Patent 6,303,607

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Gilead RANEXA ranolazine TABLET, EXTENDED RELEASE;ORAL 021526-001 Feb 12, 2007 RX Yes Yes ➤ Subscribe ➤ Subscribe TREATING CHRONIC ANGINA BY ADMINISTERING AN EXTENDED RELEASE FORM OF RANOLAZINE ➤ Subscribe
Gilead RANEXA ranolazine TABLET, EXTENDED RELEASE;ORAL 021526-002 Jan 27, 2006 RX Yes No ➤ Subscribe ➤ Subscribe TREATING CHRONIC ANGINA BY ADMINISTERING AN EXTENDED RELEASE FORM OF RANOLAZINE ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,303,607

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,562,826 Sustained release ranolazine formulations ➤ Subscribe
6,369,062 Sustained release ranolazine formulations ➤ Subscribe
6,852,724 Sustained release ranolazine formulations ➤ Subscribe
6,479,496 Methods for treating angina with ranolazine ➤ Subscribe
6,617,328 Sustained release ranolazine formulations ➤ Subscribe
6,525,057 Sustained release ranolazine formulations ➤ Subscribe
6,503,911 Sustained release ranolazine formulations ➤ Subscribe
6,620,814 Sustained release ranolazine formulations ➤ Subscribe
6,864,258 Sustained release ranolazine formulations ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,303,607

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 022085 ➤ Subscribe
Argentina 052921 ➤ Subscribe
Argentina 053440 ➤ Subscribe
Austria 217794 ➤ Subscribe
Austria 285774 ➤ Subscribe
Australia 2001240092 ➤ Subscribe
Australia 2008207703 ➤ Subscribe
Australia 2008207707 ➤ Subscribe
Australia 2008212005 ➤ Subscribe
Australia 4009201 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Covington
Colorcon
Federal Trade Commission
Cipla
Boehringer Ingelheim
Queensland Health
Cantor Fitzgerald
Cerilliant
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot